In support of our findings for cardiac glycosides, ouabain has shown activity against myeloid leukemia cell lines49,50, and in vitro effectiveness against primary patient CD34+ AML cells, although the elimination of primary LSCs was not established50,51. Here, CD34 is linked to myeloid leukemia.